IL1R1 and breast carcinoma: In addition, IL1R1 has been found to be upregulated in ALDH+ cells and plays a crucial role in driving cancer stem cell (CSC) activity, which can lead to resistance to adjuvant endocrine therapies, including tamoxifen and fulvestrant, in breast cancer and promote bone metastasis (76, 77).